Greenland Mines Wins SRX Global Investment and AnorTech Share-Exchange to Expand Rare-Earth Portfolio
GRML•Greenland Mines secured a strategic SRX Global investment and completed a share-exchange with AnorTech, advancing its North Atlantic Critical Metals Corridor in Greenland. Its mining division covers the Skaergaard precious-and-critical-metals project and pending Sarfartoq Nd-Pr rare-earths project, while its biotech arm develops an ALS therapy.
1. Strategic SRX Global Investment
Greenland Mines attracted SRX Global as a strategic investor, aligning the established minerals group behind its North Atlantic Critical Metals Corridor vision. The undisclosed capital infusion signals validation of Greenland Mines’s asset base and could bring industry relationships and downstream connections essential for scaling operations.
2. Share-Exchange Transaction with AnorTech
Greenland Mines closed a share-exchange with AnorTech, issuing equity to acquire interests in AnorTech’s Greenland critical-minerals assets. This non-cash deal broadens Greenland Mines’s portfolio without depleting its cash reserves and aligns both companies’ interests in developing regional projects.
3. Expanded Mining Asset Platform
The company’s mining division now encompasses the Skaergaard precious-and-critical-metals project and the pending Sarfartoq neodymium-praseodymium (Nd-Pr) rare-earths project. These assets position Greenland Mines between North American and European markets for essential magnet materials used in EVs, wind turbines and defense systems.
4. Biotech Arm Developing ALS Therapy
Beyond mining, Greenland Mines holds a biotech division focused on Klotho’s KLTO202 primary indication for ALS. This diversification reflects a multi-asset strategy, pairing critical-metals development with potential biopharmaceutical upside.
